Replacement therapy for Addison's disease: recent developments
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The hormone deficiencies in Addison's disease (primary adrenal insufficiency) are conventionally treated with oral glucocorticoid and mineralocorticoid replacement but the available therapies do not restore the physiological hormone levels and biorhythm. Despite such treatment these patients self-report impaired health-related quality of life (HRQoL) and recent research has indicated increased mortality. OBJECTIVE/METHODS: We review the literature and recent developments in replacement therapy. RESULTS/CONCLUSION: Patients with Addison's disease require mineralocorticoid replacement, i.e., fludrocortisone 0.05 - 0.20 mg once daily. Starting doses of glucocorticoids should be 15 - 20 mg for hydrocortisone or 20 - 30 mg for cortisone acetate, divided into two or three doses, and preferentially weight-adjusted. There are indications that the synthetic glucocorticoids have undesirable metabolic long-term effects, which make them less suitable as first-line treatment. Timed-release hydrocortisone tablets and continuous subcutaneous hydrocortisone infusion are promising new treatment modalities. Studies of replacement with the adrenal androgen dehydroepiandrosterone (DHEA) in adrenal failure have shown inconsistent benefit on HRQoL. DHEA, or possibly testosterone replacement is likely to be beneficial for selected groups of patients with Addison's disease but this remains to be shown. We here give our opinion of the best treatment and future direction of research in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“The GR is a nuclear receptor that is ubiquitously expressed in all human cells, however in multiple splice and translation variants that most likely differ between tissues and individuals [48] .”
BackgroundMineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628 · cited 1×
“, oxidised) locally in mineralocorticoid target tissues by the enzyme 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2) [29] .”
Background11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969 · cited 4×
“Furthermore, unbound cortisone circulates at concentrations similar to peak free cortisol, which provides a substrate for cortisol regeneration in peripheral tissues that express the enzyme 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) [46,47] .”
InfluentialTransdermal testosterone treatment in women with impaired sexual function after oophorectomy.
Shifren, J. L., Braunstein, G. D., Simon, J. A., Casson, P. R., Buster, J. E., Redmond, G. P., Burki, R. E., Ginsburg, E. S., Rosen, R. C., Leiblum, S. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431002 · Cited by 954
Arlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency
Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411401 · Cited by 644
DHEA in elderly women and DHEA or testosterone in elderly men.
Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054629 · Cited by 566 · cited 1×
“No consistent association between DHEA(S) levels and subjective health status have been demonstrated in the elderly, and similarly no consistent benefit of DHEA replacement [111,112] .”
BackgroundLabrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · cited 1×
“It has been estimated that the adrenals thus contribute with 30 – 50% of androgens in men and a very large proportion of androgens in women, particularly after menopause [104] .”
BackgroundNeurosteroids: biochemistry and clinical significance
Mellon, S. H., & Griffin, L. D. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00503-3 · Cited by 538
Acute Hypothalamic–Pituitary–Adrenal Responses to the Stress of Treadmill Exercise
Luger, A., Deuster, P. A., Kyle, S. B., Gallucci, W. T., Montgomery, L. C., Gold, P. W., Loriaux, D. L., & Chrousos, G. P. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705213162105 · Cited by 516
Cited by
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
“Thus, as will be discussed further in Section VII, mimicking the circadian profile of cortisol blood levels may help to minimize side effects and increase the quality of life in patients with adrenal insufficiency (367, 368).”
Review: Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy
Chan, S., & Debono, M. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380214 · Cited by 243
Björnsdottir, S., Sundström, A., Ludvigsson, J. F., Blomqvist, P., Kämpe, O., & Bensing, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3561 · Cited by 70
Markovic, V. M., Cupic, Z., Vukojevic, V., & Kolar-Anic, L. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0037 · Cited by 54
Metadata
- Authors
- Løvås, K., & Husebye, E. S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-03-25
- Volume
- 17
- Issue
- 4
- Pages
- 497-509
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2156164215
- Cited by
- 32
- References
- 40
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Replacement therapy for Addison's disease: recent developments. https://app.cochat.ai/papers/10.1517/13543784.17.4.497
- The paper
- Løvås, K., & Husebye, E. S. (2008). Replacement therapy for Addison's disease: recent developments. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.17.4.497
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.